top of page

The latest from NuvOx
Search
Oct 28, 2024
NuvOx Announces Two New Publications
NuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine...
Oct 14, 2024
NuvOx’s Co-Founder, Dr. Evan Unger, Receives 2024 Harry Fischer Award for Excellence in Contrast Media Research
Tucson, AZ – October 9, 2024 - Dr. Evan Unger, Executive Chairman of NuvOx Therapeutics (NuvOx), has been awarded the 2024 Harry Fischer...
Sep 17, 2024
NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products
Tucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...
Jul 11, 2024
NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada
Tucson, AZ, June 30th, 2024 – NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND:...
Jan 8, 2024
NuvOx Pharma Announces Issuance of a New Patent
Tucson, AZ, January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and...
Nov 2, 2023
NuvOx Announces Contract to Support NOVEL Trial
Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic...
Oct 2, 2023
NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School
Tucson, AZ, September 28th, 2023 NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the...
Sep 25, 2023
NuvOx Closed Oversubscribed Convertible Notes
Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round,...
Aug 30, 2023
NuvOx Announces Publication of Research Article in Cancer Research Communication
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a...
Aug 14, 2023
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...
Jun 7, 2023
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
Apr 19, 2023
NuvOx Receives SPAN Grant
NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, ...

Mar 5, 2023
NuvOx Newly Issued US Patent
The issued patent has claims for methods of use of DDFPe for stroke treatment.


Oct 11, 2022
May 19, 2022
NuvOx Pharma Announces Issuance of a New Patent
Award of this patent broadens NuvOx’s extensive patent portfolio of perfluorocarbon-based therapeutic formulations to reverse hypoxia.
May 9, 2022
NuvOx Appoints Dr. Robert King to SAB
Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...
May 9, 2022
NuvOx Technology Featured in Prominent Peer Review Journal
Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...
May 9, 2022
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...
Mar 4, 2022
NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program
On February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...
Feb 9, 2022
NuvOx to Participate in the BIO CEO Investor Conference
Tucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
bottom of page